Durvalumab after concurrent chemoradiation has significantly improved survival in stage III non-small cell lung cancer (NSCLC). However, there is limited data evaluating the utilization and challenges to deliver durvalumab consolidation in the real world. We assessed the use of consolidative durvalumab at a large academic center to examine clinical limitations to delivery of this practice-changing regimen. We found that despite incorporating consolidative durvalumab into standard practice for stage III unresectable NSCLC, 27% patients did not initiate this treatment, largely due to disease progression or toxicity from chemoradiation.

中文翻译：

---

在不可切除的 III 期非小细胞肺癌中应用和阻止巩固性 durvalumab 的因素

同步放化疗后的 Durvalumab 显着提高了 III 期非小细胞肺癌 (NSCLC) 的生存率。然而，评估在现实世界中实施 durvalumab 整合的利用率和挑战的数据有限。我们在一个大型学术中心评估了巩固性 durvalumab 的使用，以检查这种改变实践的方案的临床局限性。我们发现，尽管将巩固性 durvalumab 纳入 III 期不可切除 NSCLC 的标准实践中，但 27% 的患者并未开始这种治疗，这主要是由于疾病进展或放化疗引起的毒性。